Though androgenic steroids have been administered in muscular dystrophy without obvious clinical benefit,1,2 it is conceivable that such therapy might nonetheless ameliorate the course of this disease. This is not an unreasonable possibility in view of the well-established protein anabolic3,4 and musculotrophic properties5-8 of such agents and the recognized variability in the rate of physical deterioration in this condition which might mask less dramatic though nonetheless beneficial effects. It was felt that such trials would necessitate pharmacologic dosages of an androgenic steroid, since no evidence of a deficiency of endogenous androgens in childhood or juvenile muscular dystrophy has appeared to date. It is well recognized, of course, that disturbances of gonadal and adrenocortical steroid production and other endocrinopathy may be a frequent feature of another form of muscular dystrophy, i. e., in dystrophia myotonica or Steinert's disease.9,10
Materials and Methods
Thirteen boys and two adults with
VAN DIERMEN J, WRATNEY MJ, MATEER FM, DANOWSKI TS. Muscular Dystrophy: IX. Body Growth, Muscle Strength, and Serum Solutes During Methyltestosterone-KCl Therapy. AMA Am J Dis Child. 1959;97(4):439–444. doi:https://doi.org/10.1001/archpedi.1959.02070010441009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: